News | January 12, 2022
Veristat supported marketing applications for 12 % of all FDA Novel Drug Approvals in 2021
This surpasses the number of approvals supported in 2020
This surpasses the number of approvals supported in 2020
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
Acute therapies continue to report strong growth compared to chronic ones.
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
